Intravenous thrombolysis with urokinase for acute cerebral infarctions(within 6h from symptom onset)
陈清棠,贺茂林,徐忠宝,康德宣,赵永春,赵家壁,饶明俐,冯加纯,姚景莉,陆雪芬,徐恩,赵庆杰,武成斌,李正仪,李绍英,田时雨,苏镇培,黄远桂,苏炳华,陈峰
DOI: https://doi.org/10.3969/j.issn.1003-2754.2001.05.001
2001-01-01
Abstract:Objective This is a pilot study of a 5-year National Project,also an open-label clinical trial. The purpose is to evaluate the efficacy and safety of urokinase (UK) in the treatment of acute cerebral infactions within 6h from symptom onset. Methods Patients consistent with the inclusion criteria received UK 0.5~1.5 MU in normal saline (NS) 100~200ml intravenously over 30 min. Then 500ml of low molecular dextran was infused intravenously per day for 10 days. 24h after thrombolysis,300mg of aspirin was administered per day for 10 days and then 100mg per day for 80 days. The European Stroke Scale (ESS) was used to evaluate the neurological deficits and the ESS scores were recorded on the following time points: pretherapy,2h,24h,3d,7d,14d,30d and 90d after thrombolysis. Results 409 patients were consistent with the inclusion criteria. The dosage of UK was 1.31 MU on average. ESS scores increased rapidly after thrombolysis. ESS scores increased ≥ 10 points in 87.53% pateints at 24h after therapy. At 90d after therapy,46.6% patients had the ESS scores ≥ 95.In our study,the non-symptomatic hemorrhagic rate was 4.65% (19/409),symptomatic hemorrhagic rate was 3.91% (16/409). The mortality rate was 12.22% (50/409),in which,6.35% (26/409) died of large infarctions,1.90%,(8/409) died of intraparenchymal hemorrhage. Conclusion This study reveale that UK is effective in treatment of acute cerebral infarctions within 6h from symptom onset and ralatively safe if the indications are strictly controlled. The results will be further confirmed by the second phase of the National Projecte,a multicenter,randomized,double-blind,placebo controlled clinical study which will be finished by the end of 2000.